Rock Springs Capital RXDX Position
Exited9-Fund ConvergenceRock Springs Capital exited their position in Prometheus Biosciences Inc. (RXDX) in Q2 2023, after holding the stock for 2 quarters.
The position was first reported in Q1 2023 and has been tracked across 2 quarterly 13F filings.
RXDX is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Tulisokibart in 14 days (Apr 30, 2026), making the timing of Rock Springs's position particularly relevant.
About Prometheus Biosciences Inc.
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
Full company profile →Rock Springs Capital RXDX Position History
Frequently Asked Questions
Does Rock Springs Capital own RXDX?
No. Rock Springs Capital exited their position in Prometheus Biosciences Inc. (RXDX) in Q2 2023. They previously held the stock for 2 quarters.
How many hedge funds own RXDX?
9 specialist biotech hedge funds currently hold RXDX, including RTW Investments, Boxer Capital, Cormorant Asset Management and 6 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy RXDX?
Rock Springs Capital's position in RXDX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's RXDX position increasing or decreasing?
Rock Springs Capital completely exited their RXDX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
RXDXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →